Andreoli, Michael T., et al. “Feasibility and Efficacy of a Mass Switch from Ranibizumab (Lucentis) to Bevacizumab (Avastin) for Treatment of Neovascular Age-Related Macular Degeneration”. Digital Journal of Ophthalmology, vol. 21, no. 3, Sept. 2015, pp. 29-34, doi:10.5693/djo.01.2015.04.002.